Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Pfizer’s Elrexfio improves progression-free survival in Phase 3 multiple myeloma trial

By Public Technologies
  • Pfizer’s Elrexfio met the primary endpoint in the Phase 3 MagnetisMM-32 trial, outperforming standard regimens in relapsed or refractory multiple myeloma.
  • Treatment reduced the risk of disease progression or death in patients previously treated with anti-CD38 therapy and lenalidomide.
  • No new safety signals emerged, though severe infections were more frequent with Elrexfio than with comparator treatments.
  • The findings support potential use in earlier treatment lines; planned submissions to global health authorities will seek regulatory review.
  • Topline results were announced; detailed findings will be presented at a future medical meeting and submitted for publication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610270645BIZWIRE_USPR_____20261027_BW750216) on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.